Only Dymista offers fast relief and inflammation control—with every dose1,2

DYMISTA (azelastine HCl/fluticasone propionate) Nasal Spray Offers Fast Relief and Inflammation Control with every dose in patients 12 years of age and older

First timepoint (30 minutes) at which Dymista significantly improved, and continued to improve, seasonal nasal allergy symptoms vs placebo in patients age 12 years and older.1

  • 30 minutes fast.onset in as soon as a half hour vs placebo1
  • Blocks Histamine.1
  • Reduces Inflammation. via metered-dose spray pump1
  • Offers a Fine Mist Spray.1
  • Delivers Precisely.
  • Treats Symptoms Better vs azelastine HCI or fluticasone propionate comparators1,3,b,c

Symptom relief was measured by change from baseline in the placebo-subtracted mean reflective total nasal symptom score (rTNSS) for each day (maximum score 24), averaged over the 14-day study period.1,3

Dymista provided a significant improvement in TNSS compared with both azelastine HCI and fluticasone propionate comparators. The azelastine HCl and fluticasone propionate comparators used the same device and vehicle as Dymista and are not commercially marketed.1,3

References: 1. Dymista [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc., a Mylan Company; 2015. 2. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-1289.e10. 3. Data on file. Meda Pharmaceuticals Inc., a Mylan Company; 2015.


  • Somnolence: Avoid engaging in hazardous occupations requiring complete mental alertness such as driving or operating machinery when taking DYMISTA.
  • Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with DYMISTA because further decreased alertness and impairment of CNS performance may occur.
  • Epistaxis, nasal ulcerations, nasal septal perforation, impaired wound healing, Candida albicans infection: Monitor patients periodically for signs of adverse effects on the nasal mucosa. Avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma.
  • Glaucoma or posterior subcapsular cataracts: Monitor patients closely with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.
  • Potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. More serious or even fatal course of chickenpox or measles in susceptible patients. Use caution in patients with the above because of the potential for worsening of these infections.
  • Hypercorticism and adrenal suppression with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue DYMISTA slowly.
  • Potential reduction in growth velocity in children. Monitor growth routinely in pediatric patients receiving DYMISTA.
  • Potent inhibitors of cytochrome P450 (CYP) 3A4: May increase blood levels of fluticasone propionate.
  • Ritonavir: Coadministration is not recommended.
  • Other potent CYP3A4 inhibitors, such as ketoconazole: use caution with coadministration.
  • The most common adverse reaction (≥2% incidence) are dysgeusia, epistaxis, and headache.


DYMISTA contains an H1-receptor antagonist and a corticosteroid, and is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 6 years of age and older who require treatment with both azelastine hydrochloride and fluticasone propionate for symptom relief.

Please see the Full Prescribing Information.